Blueprint Medicines Announces R&D Leadership Transitions Becker Hewes, M.D., promoted to Chief Medical Officer Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company s research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral, M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and biostatistics. In his new
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
Beam TherapeuticsJanuary 11, 2021 GMT
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate Walsh, president and chief executive officer of the Boston Medical Center (BMC) health system, has joined the company’s board of directors. BMC is a private, not-for-profit, academic medical center with a community-based focus and is the primary teaching affiliate of Boston University School of Medicine.
Published: Jan 07, 2021
WALTHAM, Mass. (BUSINESS WIRE) TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors. Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.
Prior to joining Freeline in 2018, Mr. Silver was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to Perella Weinberg, Mr. Silver held a number of positions in Morgan Stanley’s healthcare investment banking group, most recently as Managing Director from 1998 to 2013. He began his career in the corporate transactions group at Sullivan & Cromwell. His advisory experience spans dozens of transactions, including mergers and acquisitions, joint ventures an
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months
December 22, 2020 07:00 ET | Source: ONL Therapeutics ONL Therapeutics Ann Arbor, Michigan, UNITED STATES
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it closed on $46.9 million in a Series B Preferred Stock financing round. The financing included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round includ